Clinical Trial Update: A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SHR-1210 in combination with Apatinib as first-line therapy for advanced hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Locally Advanced or Metastatic and Unresectable HCC | Phase 3 | Status: COMPLETED | Results posted: 2024-02-06